• LSL Pharma announced Chief Financial Officer Luc Mainville exited the role, effective immediately.
• President and CEO François Roberge took over as interim CFO while the company runs a formal search.
• Audit Committee oversight continues under chair Mario Paradis during the transition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LSL Pharma Group Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609100700CANADANWCANADAPR_C5257) on September 10, 2026, and is solely responsible for the information contained therein.